Quantifying clinical relevance in the treatment of schizophrenia
- PMID: 22177377
- PMCID: PMC3298768
- DOI: 10.1016/j.clinthera.2011.11.016
Quantifying clinical relevance in the treatment of schizophrenia
Abstract
Background: To optimize the management of patients with schizophrenia, quantification of treatment effects is crucial. While in research studies, the use of quantitative assessments is ubiquitous, this is not the case in routine clinical practice, creating an important translational practice gap.
Objective: The aim of this study was to examine the relevance, methodology, reporting, and application of measurement-based approaches in the management of schizophrenia.
Methods: We summarized methodological aspects in the assessment of therapeutic and adverse antipsychotic effects in schizophrenia, including definitions and methods of measurement-based assessments and factors that can interfere with the valid quantification of treatment effects. Finally, we proposed pragmatic and clinically meaningful ways to measure and report treatment outcomes.
Results: Although rating scales are ubiquitous in schizophrenia research and provide the evidence base for treatment guidelines, time constraints and lack of familiarity with and/or training in validated assessment tools limit their routine clinical use. Simple but valid assessment instruments need to be developed and implemented to bridge this research-practice gap. In addition, results from research trials need to be communicated in clinically meaningful ways, including the reporting of effect sizes, numbers-needed-to-treat and -harm, confidence intervals, and absolute risk differences. Some important outcomes, such as treatment response, should be reported in escalating intervals using incrementally more stringent psychopathology improvements. Even with quantification, it remains challenging to weigh individual efficacy and adverse effect outcomes against one another and decide on the targeted or desired improvement or outcomes while also incorporating these in patient-centered and shared decision methods.
Conclusions: Quantification of treatment effects in schizophrenia is relevant for patient management, research, and the evaluation of health care systems. Beyond consensus about meaningful outcomes definitions, reporting strategies, pragmatic tool development and implementation, the discovery of novel treatment mechanisms and related biomarkers is hoped to advance measurement-based approaches in schizophrenia and thereby improve patient outcomes.
Copyright © 2011 Elsevier HS Journals, Inc. All rights reserved.
Figures
Similar articles
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Past and present progress in the pharmacologic treatment of schizophrenia.J Clin Psychiatry. 2010 Sep;71(9):1115-24. doi: 10.4088/JCP.10r06264yel. J Clin Psychiatry. 2010. PMID: 20923620 Free PMC article. Review.
-
Comparing symptom response among antipsychotic medications in CATIE.J Clin Psychopharmacol. 2013 Feb;33(1):123-6. doi: 10.1097/01.jcp.0000426178.43831.ed. J Clin Psychopharmacol. 2013. PMID: 23288232 No abstract available.
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
-
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders.Aust N Z J Psychiatry. 2005 Jan-Feb;39(1-2):1-30. doi: 10.1080/j.1440-1614.2005.01516.x. Aust N Z J Psychiatry. 2005. PMID: 15660702 Review.
Cited by
-
Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants.World Psychiatry. 2022 Jun;21(2):295-307. doi: 10.1002/wps.20972. World Psychiatry. 2022. PMID: 35524620 Free PMC article.
-
What Is the Minimum Clinically Important Change in Negative Symptoms of Schizophrenia? PANSS Based Post-hoc Analyses of a Phase III Clinical Trial.Front Psychiatry. 2022 Apr 25;13:816339. doi: 10.3389/fpsyt.2022.816339. eCollection 2022. Front Psychiatry. 2022. PMID: 35546918 Free PMC article.
-
What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?World Psychiatry. 2018 Jun;17(2):149-160. doi: 10.1002/wps.20516. World Psychiatry. 2018. PMID: 29856543 Free PMC article.
-
Bridging the Measurement Gap Between Research and Clinical Care in Schizophrenia: Positive and Negative Syndrome Scale-6 (PANSS-6) and Other Assessments Based on the Simplified Negative and Positive Symptoms Interview (SNAPSI).Innov Clin Neurosci. 2017 Dec 1;14(11-12):68-72. Innov Clin Neurosci. 2017. PMID: 29410939 Free PMC article.
-
Efficacy and Safety of Transcranial Direct Current Stimulation for Treating Negative Symptoms in Schizophrenia: A Randomized Clinical Trial.JAMA Psychiatry. 2020 Feb 1;77(2):121-129. doi: 10.1001/jamapsychiatry.2019.3199. JAMA Psychiatry. 2020. PMID: 31617873 Free PMC article. Clinical Trial.
References
-
- Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J, McIntyre JS, Charles SC, Altshuler K, Cook I, Cross CD, Mellman L, Moench LA, Norquist G, Twemlow SW, Woods S, Yager J, Gray SH, Askland K, Pandya R, Prasad K, Johnston R, Nininger J, Peele R, Anzia DJ, Benson RS, Lurie L, Walker RD, Kunkle R, Simpson A, Fochtmann LJ, Hart C, Regier D. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2):1–56. - PubMed
-
- National Institute for Clinical Excellence. Schizophrenia: Full national guideline on core interventions in primary and secondary care. Royal College of Psychiatrists. 2003
-
- Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) - Guidelines for biological treatment of schizophrenia, part 1: Acute treatment of schizophrenia. World J BiolPsychiatry. 2005;6(3):132–191. - PubMed
-
- McGorry PD. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry. 2005;39(1-2):1–30. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous